Publikationen
Eine vollständige Liste der Publikationen von Herrn Prof. Dr. Günther Weindl und Herrn PD Dr. Christian Tränkle können Sie über PubMed abrufen.
2024
Holze J, Lauber F, Kostenis E, Weindl G (2024) Label-free biosensor assay decodes the dynamics of Toll-like receptor signaling. bioRxiv 2024.01.18.576268
Kraft F, Enns J, Honin I, Engelhardt J, Schöler A, Smith S, Meiler J, Schäker-Hübner L, Weindl G, Hansen FK (2024) Groebke Blackburn Bienaymé-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory properties. Bioorg Chem 143:107072.
Immunology 171:181-197.
2023
Bockstiegel J, Engelhardt J, Weindl G (2023) P2X7 receptor activation leads to NLRP3-independent IL-1β release by human macrophages. Cell Commun Signal 21(1):335.
Brandenburg K, Ferrer-Espada R, De Tejada GM, Nehls C, Fukuoka S, Mauss K, Weindl G, Garidel P (2023) A Comparison between SARS-CoV-2 and Gram-Negative Bacteria-Induced Hyperinflammation and Sepsis.Int J Mol Sci 24:15169.
Bockstiegel J, Wurnig SL, Engelhardt J, Enns J, Hansen FK, Weindl G (2023) Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1β release. Biochem Pharmacol 215:115693.
2022
Möller C, Heinbockel L, Garidel P, Gutsmann T, Mauss K, Weindl G, Fukuoka S, Loser D, Danker T, Brandenburg K (2022) Toxicological and Safety Pharmacological Profiling of the Anti-Infective and Anti-Inflammatory Peptide Pep19-2.5. Microorganisms 10:2412.
2021
Dolšak A, Šribar D, Scheffler A, Grabowski M, Švajger U, Gobec S, Holze J, Weindl G, Wolber G, Sova M (2021) Further hit optimization of 6-(trifluoromethyl)pyrimidin-2-amine based TLR8 modulators: Synthesis, biological evaluation and structure–activity relationships. Eur J Med Chem 225:113809.
Brandenburg K, Schromm AB, Weindl G, Heinbockel L, Correa W, Mauss K, Martinez de Tejada G, Garidel P (2021) An update on endotoxin neutralization strategies in Gram-negative bacterial infections. Expert Rev Anti Infect Ther 19:495-517.
Klionsky DJ, ..., Weindl G, ..., Tong CK (2021) Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy 17:1-382.
Weindl G (2021) Immunocompetent human intestinal models in preclinical drug development. Handb Exp Pharmacol 265:219-233.
Heinbockel L. Weindl G, Correa W, Brandenburg J, Reiling, N, Wiesmüller KH, Schürholz T, Gutsmann T., Martinez de Tejada G, Mauss K, Brandenburg K (2021) Anti-Infective and Anti-Inflammatory Mode of Action of Peptide 19-2.5. Int J Mol Sci 22:1465.
2020
Holze J, Bermudez M, Pfeil EM, Kauk M, Bödefeld T, Irmen M, Matera C, Dallanoce C, De Amici M, Holzgrabe U, König GM, Tränkle C, Wolber G, Schrage R, Mohr K, Hoffmann C, Kostenis E, Bock A (2020) Ligand-Specific Allosteric Coupling Controls G-Protein-Coupled Receptor Signaling. ACS Pharmacol Transl Sci 3:859-867.
Müller G, Lübow C, Weindl G (2020) Lysosomotropic beta blockers induce oxidative stress and IL23A production in Langerhans cells. Autophagy 16:1380-1395.
Hering H, Zoschke C, Kühn M, Gadicherla AK, Weindl G, Luch A, Schreiver I (2020) TatS—a novel in vitro tattooed human skin model for improved pigment toxicology research. Arch Toxicol 94:2423-2434.
Matucci R, Bellucci C, Martino MV, Nesi M, Manetti D, Welzel J, Bartz U, Holze J, Tränkle C, Mohr K, Mazzolari A, Vistoli G, Dei S, Teodori E, Romanelli MN (2020) Carbachol dimers with primary carbamate groups as homobivalent modulators of muscarinic receptors. Eur J Pharmacol 883:173183.
Bermudez M, Grabowski M, Murgueitio MS, Tiemann N, Varga P, Rudolf T, Wolber G, Weindl G, Rademann J (2020) Biological characterization, mechanistic investigation and structure-activity relationships of chemically stable TLR2 antagonists. ChemMedChem 15:1364-1371.
Grabowski M, Bermudez M, Rudolf T, Šribar D, Varga P, Murgueitio MS, Wolber G, Rademann J, Weindl G (2020) Identification and validation of a novel dual small-molecule TLR2/8 antagonist. Biochem Pharmacol 177:113957.
Lübow C, Bockstiegel J, Weindl G (2020) Lysosomotropic drugs enhance pro-inflammatory responses to IL-1β in macrophages by inhibiting internalization of the IL-1 receptor. Biochem Pharmacol 175:113864.
Grabowski M, Murgueitio MS, Bermudez M, Wolber G, Weindl G (2020) The novel small-molecule antagonist MMG-11 preferentially inhibits TLR2/1 signaling. Biochem Pharmacol 171:113687.
2019
Šribar D, Grabowski M, Murgueitio MS, Bermudez M, Weindl G, Wolber G (2019) Identification and characterization of a novel chemotype for human TLR8 inhibitors. Eur J Med Chem 179:744-752.
Brandenburg K, Heinbockel L, Weindl G, Wiesmüller KH, Schürholz T, Correa W, Gutsmann T, Mauss K, Martinez-de-Tejada G, Garidel P (2019) Development of Antimicrobial Peptides Based on Limulus Anti-Lipopolysaccharide Factor (LALF). In: Williams K. (eds) Endotoxin Detection and Control in Pharma, Limulus, and Mammalian Systems. Springer, Cham. p. 683-706.
Schramm S, Agnetta L, Bermudez M, Gerwe H, Irmen M, Holze J, Littmann T, Wolber G, Tränkle C, Decker M (2019) Novel BQCA- and TBPB-Derived M1 Receptor Hybrid Ligands: Orthosteric Carbachol Differentially Regulates Partial Agonism. ChemMedChem. 14:1349-1358.
Pfalzgraff A, Correa W, Heinbockel L, Schromm AB, Lübow C, Gisch N, Martinez-de-Tejada G, Brandenburg K, Weindl G (2019) LPS-neutralizing peptides reduce outer membrane vesicle-induced inflammatory responses. Biochim Biophys Acta Mol Cell Biol Lipids. 1864:1503-1513.
Pfalzgraff A, Weindl G (2019) Intracellular lipopolysaccharide sensing as a potential therapeutic target for sepsis. Trends Pharmacol Sci 40:187-197.
Correa W, Heinbockel L, Martinez-de-Tejada G, Sanchez S, Garidel P, Schürholz T, Mier W, Dupont A, Hornef M, Gutsmann T, Mauss K, Weindl G, Brandenburg K (2019) Synthetic anti-lipopolysaccharide peptides (SALP) as effective inhibitors of pathogen-associated molecular patterns (PAMPs). Adv Exp Med Biol 1117:111-129.
Klaschik K, Hauke J, Neidhardt G, Tränkle C, Surowy HM, Heilmann-Heimbach S, Rappl G, Mangold E, Arnold N, Niederacher D, Sutter C, Burwinkel B, Engel C, Wappenschmidt B, Meindl A, Ernst C, Weber-Lassalle K, Weber-Lassalle N, Schmidt S, Borde J, Schmutzler RK, Hahnen E, Pohl-Rescigno E (2019) The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers. Int J Cancer 144:1761-1763.
Publikationen Prof. Dr. Weindl
Hier finden Sie eine Übersicht der Publikationen von Herrn Prof. Dr. Weindl von 2014 bis 2018.
Publikationen PD Dr. Tränkle
Hier finden Sie eine Übersicht der Publikationen von Herrn PD Dr. Tränkle von 2014 bis
2018.